Generic Lazanda Availability
Last updated on Apr 10, 2025.
Lazanda is a brand name of fentanyl, approved by the FDA in the following formulation(s):
LAZANDA (fentanyl citrate - spray, metered;nasal)
-
Manufacturer: BTCP PHARMA
Approval date: June 30, 2011
Strength(s): EQ 0.1MG BASE (discontinued) [RLD], EQ 0.4MG BASE (discontinued) [RLD] -
Manufacturer: BTCP PHARMA
Approval date: December 21, 2015
Strength(s): EQ 0.3MG BASE (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lazanda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Container
Patent 9,731,869
Issued: August 15, 2017
Inventor(s): Walsh Philip & Watts Peter
Assignee(s): Archimedes Development LimitedA container (), comprising a thread () arranged around an opening () for engaging a corresponding thread () of a closure (), more than four retention members () arranged around the opening (), each retention member () having an end-face for abutting a member () on an interior surface of the closure () to impede unthreading of the closure (), the retention members () being arranged such that a tangent () to each end-face of the retention members () intersects a plane () bisecting the container () at an obtuse angle (), wherein the retention members () are arranged in first and second groups, the first group () comprising one retention member () having an end-face substantially parallel to the plane bisecting the container (), and the second group () comprising two or more retention members (), the first and second groups being arranged on one side of the plane (), each in a respective quadrant of the container (), the teeth of the second group () have a first inter-tooth spacing, and a second inter-tooth spacing is provided between an end-face of the retention member of the first group () and a first retention member of the second group (), and the second inter-tooth spacing is larger than the first inter-tooth spacing.
Patent expiration dates:
- January 26, 2032✓
- January 26, 2032
More about Lazanda (fentanyl)
- Lazanda consumer information
- Check interactions
- Compare alternatives
- Reviews (2)
- Latest FDA alerts (14)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: Opioids (narcotic analgesics)
- Breastfeeding
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.